Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.
Lower-dose dasatinib appears effective in chronic myeloid leukemia, potentially reducing side effects without sacrificing disease control in a widely-treated population.
This pooled analysis from a major leukemia center evaluates lower-dose dasatinib (50 mg/d) outcomes, with implications for dose optimization in CML management. If confirmed, this supports a dose-reduction strategy that could reduce side effects without compromising efficacy in a widely-treated patient population.
What the study was
- Study design
- Pooled analysis / retrospective cohort
- Population
- CML/leukemia patients on dasatinib 50 mg/d (reduced dose)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical Lymphoma, Myeloma & Leukemia
Why it surfaced
Dose optimization data from a high-volume center for a widely-used TKI; pooled analysis from MD Anderson is high credibility; directly practice-relevant for CML management.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.